Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers. Jansen RA, Mainardi S, Dias MH, Bosma A, et al. Proc Natl Acad Sci U S A 2024;121:e2319492121.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jansen RA, Mainardi S, Dias MH, Bosma A, et al. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers. Proc Natl Acad Sci U S A 2024;121:e2319492121.
PMID: 38377196